Unlock Insights into Stroke Research | Specialized Experimental Model Solutions
Ace Therapeutics' Collagenase-Induced ICH Model offers a robust, reproducible, and pathophysiologically relevant platform to accelerate preclinical ICH research and therapeutic development. This brochure provides a comprehensive overview of our collagenase-induced ICH model, detailing how it supports mechanistic studies and translational drug evaluation across multiple stages of hemorrhagic stroke research.
A Gold-Standard Model for Hemorrhagic Stroke
- Progressive hematoma formation that more closely mimics spontaneous human ICH than whole-blood injection models
- Highly reproducible lesion size and location, enabling consistent and interpretable outcomes
- Tunable injury severity, allowing modeling of mild to severe hemorrhage through collagenase dose adjustment .
Capturing Secondary Brain Injury Mechanisms
- Robust perihematomal edema and neuroinflammatory responses
- Modeling of ischemic penumbra and secondary tissue damage
- Ideal for evaluating neuroprotective, anti-inflammatory, and edema-reducing therapies
Comprehensive Functional and Pathological Readouts
- Neurological and behavioral assessments to quantify functional impairment
- Sensorimotor tests including placement and corner turn assays
- Brain water content analysis for objective measurement of cerebral edema
Designed for Translational ICH Drug Development
Ace Therapeutics' collagenase-induced ICH model supports a wide range of research and development objectives, including:
- Pathogenesis and mechanism-of-action studies in hemorrhagic stroke
- Preclinical efficacy testing of small molecules, biologics, and cell-based therapies
- Investigation of post-ICH inflammation, edema, and multi-organ dysfunction
Discover how the Ace Therapeutics Collagenase-Induced ICH Model can help you generate meaningful, decision-driving preclinical data in hemorrhagic stroke research.